Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Combined use of drug-coated balloon (DCB) and cutting balloon angioplasty (CBA) in the treatment of acute coronary syndrome

Yuguo Liu^1,2, Lei Guo², Ji Zhao², Shaoke Meng², Bo Zhang², Hao Zhu², Ning Yang³, Yuming Li³

¹Department of Cardiology, TEDA International Cardiovascular Hospital, Tianjin Medical University Clinical Cardiovascular Institute, Tianjin 300457, China; ²Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China; ³Department of Cardiology, Tianjin Economic-Technological Development Area (TEDA) International Cardiovascular Hospital, Tianjin 300457, China.

For correspondence:- Yuming Li Email: cardiolab@live.com

Accepted: 26 March 2023 Published: 29 April 2023

Citation: Liu Y, Guo L, Zhao J, Meng S, Zhang B, Zhu H, et al. Combined use of drug-coated balloon (DCB) and cutting balloon angioplasty (CBA) in the treatment of acute coronary syndrome. Trop J Pharm Res 2023; 22(4):893-899 doi: 10.4314/tjpr.v22i4.24

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the effectiveness and safety of combined use of drug-coated balloon (DCB) and cutting balloon angioplasty (CBA) in patients with acute coronary syndrome (ACS).

Methods: One hundred and fifty-six patients with ACS undergoing DCB or CBA from January 2019 to January 2021 served as subjects in this study. There were 30 in-stent re-stenosis (ISR) patients in group A, 31 ISR patients in group B, 61 de novo patients in group C, and 34 de novo patients in group D. Baseline characteristics, high-risk factors, biochemical indices, incidence of intervention-related complications, and major adverse cardiovascular events (MACE) were compared amongst the groups, before and after operation.

Results: Group B had a higher immediate minimum lumen diameter (MLD) after operation than group A, and group D had higher immediate MLD after operation than group C. Group B produced higher acute gain after intervention than group A, but post-intervention acute gain was greater in group D than in group C. There were significant differences in late luminal loss (LLL) amongst the groups (p = 0.013), but LLL was comparable in groups A and B (p = 0.411), and in groups C and D (p = 0.434). During the follow-up period, the incidence of MACE in group A was significantly greater than in group B, but MACE in group C was comparable to that in group D.

Conclusion: Combined treatment with CBA and DCB significantly improves postoperative immediate MLD and acute gain after intervention in patients with ISR lesions or de novo lesions, without reducing long-term effectiveness and safety. Multi-center trials involving larger number of patients will be required to validate the results from this study.

Keywords: Drug-coated balloon, Cutting balloon angioplasty, In-stent restenosis, de novo lesion, Clinical outcome